<DOC>
	<DOCNO>NCT00672620</DOCNO>
	<brief_summary>The purpose study determine efficacy safety vortioxetine , daily ( QD ) , adult major depressive disorder .</brief_summary>
	<brief_title>Efficacy Safety Vortioxetine ( Lu AA21004 ) Treatment Patients With Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call Vortioxetine . Vortioxetine test treat depression adult major depressive disorder ( MDD ) . This study look MDD relief people take vary dosage vortioxetine . The study enrol 611 patient . Participants randomly assign ( chance , like flip coin ) one four treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 2.5 mg - Vortioxetine 5 mg - Duloxetine 10 mg - Placebo ( dummy inactive capsule ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct United States . The overall time participate study 12 week . Participants make 8 visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Suffers major depressive episode primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criterion . The report duration current major depressive episode least 3 month . Has 1 follow : Any current psychiatric disorder major depressive disorder define DSMIVTR . Current past history : manic hypomanic episode , schizophrenia , psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Any substance disorder ( except nicotine caffeine ) within previous 6 month define DSMIVTR . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder might compromise study . Has significant risk suicide accord investigator 's opinion score ≥5 item 10 ( suicidal thought ) Montgomery Åsberg Depression Rating Scale ( MADRS ) make suicide attempt previous 6 month . The current depressive symptom patient consider investigator resistant 2 adequate antidepressant treatment least 6 week duration . Has receive electroconvulsive therapy within 6 month prior Screening . Is currently receive formal cognitive behavioral therapy , systematic psychotherapy , plan initiate therapy study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Major Depressive Episode</keyword>
</DOC>